Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
Saved in:
| Title: | Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition. |
|---|---|
| Authors: | Gu CL; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Zhu HX; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Deng L; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Meng XQ; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Li K; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Xu W; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Zhao L; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Liu YQ; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China., Zhu ZP; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China. zhuzhenping@3sbio.com., Huang HM; Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., 3SBio Inc. Company, Shanghai, 201203, China. huanghaomin@3s-guojian.com. |
| Source: | Acta pharmacologica Sinica [Acta Pharmacol Sin] 2022 Mar; Vol. 43 (3), pp. 672-680. Date of Electronic Publication: 2021 May 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
